Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial

Pagel, JM; Soumerai, J; Reddy, N; Jagadeesh, D; Stathis, A; Asch, A; Salman, H; Kenkre, VP; Iasonos, A; Llorin-Sangalang, J; Li, JN; Zelenetz, A

Zelenetz, A (通讯作者)，Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.

LANCET ONCOLOGY, 2022; 23 (8): 1021

Abstract

Background Phosphatidylinositol 3-kinase p110 delta (PI3K delta) inhibitors are efficacious in B-cell malignancies. Immune -related adverse events mig......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索